Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
Status:
Completed
Trial end date:
2015-05-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Peginterferon Lambda-1a (Lambda) combined
with Ribavirin (RBV) and Telaprevir (TVR) is effective in the treatment of chronic Hepatitis
C (CHC) compared to Peginterferon Alfa-2a (alfa-2a) combined with RBV and Telaprevir.